Getein Biotech, Inc (SHA:603387)
China · Delayed Price · Currency is CNY 8.75
0.00 (0.00%)
At close: Jan 23, 2026
Getein Biotech Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Net Income | 208.76 | 223.64 | 279.77 | 498.91 | 398.99 | 304.73 | Upgrade |
Depreciation & Amortization | 92.29 | 92.29 | 93.08 | 70.35 | 49.4 | 35.93 | Upgrade |
Other Amortization | 7.16 | 7.16 | 8.77 | 7.79 | 7.13 | 6.02 | Upgrade |
Loss (Gain) From Sale of Assets | -1.59 | -1.59 | -0.67 | -0.02 | -1.05 | -0.57 | Upgrade |
Asset Writedown & Restructuring Costs | 31.15 | 31.15 | 1.69 | 0.53 | 0.1 | - | Upgrade |
Loss (Gain) From Sale of Investments | -2.27 | -2.27 | -26.31 | -34.63 | -23.56 | -42.54 | Upgrade |
Provision & Write-off of Bad Debts | 13.7 | 13.7 | 19.21 | 22.87 | 8.36 | 12.48 | Upgrade |
Other Operating Activities | 7.37 | 7.11 | 29.77 | 37.37 | 31.26 | 41.59 | Upgrade |
Change in Accounts Receivable | 23.66 | 23.66 | -2.45 | -111.25 | -49.52 | -200.29 | Upgrade |
Change in Inventory | 3.9 | 3.9 | 17.34 | -52.25 | -43.27 | -40.26 | Upgrade |
Change in Accounts Payable | 30.24 | 30.24 | -81.06 | 53.6 | 56.13 | 60.29 | Upgrade |
Change in Other Net Operating Assets | - | - | - | - | - | 2.89 | Upgrade |
Operating Cash Flow | 408.38 | 423 | 333.22 | 482.96 | 432.36 | 185.47 | Upgrade |
Operating Cash Flow Growth | -6.47% | 26.94% | -31.00% | 11.70% | 133.12% | -17.84% | Upgrade |
Capital Expenditures | -222.77 | -156.4 | -258.13 | -217.44 | -179.6 | -113.53 | Upgrade |
Sale of Property, Plant & Equipment | 5.29 | 5.25 | 8.65 | 4.57 | 2.87 | 4.16 | Upgrade |
Cash Acquisitions | -1.57 | - | - | - | - | -54.05 | Upgrade |
Divestitures | 2.2 | 1.58 | 3.23 | - | - | - | Upgrade |
Investment in Securities | -125.62 | -153.08 | -119.8 | -586.57 | -104.75 | -99.41 | Upgrade |
Other Investing Activities | -48.43 | -45.47 | 9.22 | 39 | 26.84 | 24.12 | Upgrade |
Investing Cash Flow | -390.91 | -348.12 | -356.83 | -760.44 | -254.63 | -238.71 | Upgrade |
Short-Term Debt Issued | - | - | - | - | - | 0.79 | Upgrade |
Long-Term Debt Issued | - | 1,070 | 1,130 | 792.44 | 496.63 | 635.82 | Upgrade |
Total Debt Issued | 998.89 | 1,070 | 1,130 | 792.44 | 496.63 | 636.6 | Upgrade |
Long-Term Debt Repaid | - | -1,156 | -1,062 | -707.06 | -380.89 | -365.33 | Upgrade |
Net Debt Issued (Repaid) | -115.14 | -85.64 | 67.92 | 85.39 | 115.74 | 271.27 | Upgrade |
Issuance of Common Stock | - | - | - | - | - | 45.51 | Upgrade |
Repurchase of Common Stock | - | - | - | - | -50.38 | -0.54 | Upgrade |
Common Dividends Paid | -103.31 | -110.98 | -219.4 | -140.73 | -103.57 | -115.82 | Upgrade |
Other Financing Activities | 3.58 | -17.05 | 5.61 | 9.46 | 9.28 | -0.41 | Upgrade |
Financing Cash Flow | -214.87 | -213.67 | -145.88 | -45.88 | -28.93 | 200 | Upgrade |
Foreign Exchange Rate Adjustments | 6.27 | 5.89 | 11.67 | 19.2 | -1.02 | -6.04 | Upgrade |
Net Cash Flow | -191.13 | -132.89 | -157.81 | -304.16 | 147.78 | 140.72 | Upgrade |
Free Cash Flow | 185.61 | 266.6 | 75.09 | 265.51 | 252.77 | 71.94 | Upgrade |
Free Cash Flow Growth | -34.92% | 255.02% | -71.72% | 5.04% | 251.38% | -28.72% | Upgrade |
Free Cash Flow Margin | 17.80% | 22.89% | 5.49% | 14.57% | 18.03% | 6.40% | Upgrade |
Free Cash Flow Per Share | 0.36 | 0.53 | 0.15 | 0.52 | 0.49 | 0.14 | Upgrade |
Cash Income Tax Paid | 94.19 | 91.25 | 148.48 | 123.19 | 148.32 | 97.53 | Upgrade |
Levered Free Cash Flow | -388.29 | 474.7 | -66.49 | -269.29 | 115.56 | -102.12 | Upgrade |
Unlevered Free Cash Flow | -380.84 | 484.03 | -55.9 | -258.91 | 124.51 | -98.23 | Upgrade |
Change in Working Capital | 51.82 | 51.82 | -72.09 | -120.22 | -38.26 | -172.18 | Upgrade |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.